Modern aspects of safety of 5a-reductase inhibitors
- Autores: Vinarov A.Z1, Voskanyan G.A1, Rokhlikov I.M1, Spivak L.G1
-
Afiliações:
- Edição: Nº 6 (2012)
- Páginas: 106-109
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/279652
- ID: 279652
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Texto integral
Bibliografia
- Thompson I.M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003;349:215-224.
- Andriole G.L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010;362:1192-1202.
- Food and Drug Administration. Briefing information and slides presented at the December 1, 2010, meeting of the Oncologic Drugs Advisory Committee.
- Dutasteride label updates: GSK Advisory board meeting report. 21 March 2012. NH Eurobuilding Hotel, Madrid, Spain.
- Roehrborn C.G. et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. European Urology; Published online ahead of print 19 September 2009.
Arquivos suplementares
